ABL1 and cancer: This multi-kinase drug also inhibits Src family kinases (SFK), BCR-ABL, platelet-derived growth factor receptor (PDGFR) and c-KIT [37,38] and has previously been shown to inhibit cancer progression as well as viral infection [27,39].